- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12.25 | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | IO Biotech meldet vielversprechende 5-Jahres-Daten für Melanom-Impfstoff | 3 | Investing.com Deutsch | ||
| 15.12.25 | IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications | 2 | GlobeNewswire (USA) | ||
| 21.11.25 | IO Biotech meldet Rücktritt des Chief Accounting Officer und Neubesetzung der Position | 5 | Investing.com Deutsch | ||
| IO BIOTECH Aktie jetzt für 0€ handeln | |||||
| 21.11.25 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | Piper Sandler reiterates Overweight rating on IO Biotech stock | 3 | Investing.com | ||
| 14.11.25 | IO Biotech GAAP EPS of -$0.13 beats by $0.25 | 2 | Seeking Alpha | ||
| 14.11.25 | IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights | 469 | GlobeNewswire (Europe) | Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although... ► Artikel lesen | |
| 14.11.25 | IO Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.25 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11.25 | IO Biotech presents preclinical data for new cancer vaccine candidates | 1 | Investing.com | ||
| 07.11.25 | IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | 1 | GlobeNewswire (USA) | ||
| 20.10.25 | IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma | 801 | AFX News | KENILWORTH (NJ) (dpa-AFX) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with... ► Artikel lesen | |
| 20.10.25 | IO Biotech: Kombinationsimpfstoff bei Melanom verfehlt statistische Signifikanz knapp | 1 | Investing.com Deutsch | ||
| 20.10.25 | IO Biotech's melanoma vaccine combination narrowly misses primary endpoint | 2 | Investing.com | ||
| 20.10.25 | IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 | 165 | GlobeNewswire (Europe) | Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression... ► Artikel lesen | |
| 29.09.25 | IO Biotech stock rating downgraded to Hold by TD Cowen on FDA setback | 9 | Investing.com | ||
| 29.09.25 | H.C. Wainwright stuft IO Biotech nach Studienverzögerungen auf "Neutral" herab | 1 | Investing.com Deutsch | ||
| 29.09.25 | IO Biotech stock downgraded to Neutral by H.C. Wainwright on trial delays | 2 | Investing.com | ||
| 29.09.25 | IO Biotech stock plummets after FDA recommends against BLA submission | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,762 | -0,27 % | Valneva Aktie: 2 Euro oder 8 Euro - wo liegen die nächsten Ziele? | Die Valneva Aktie hat turbulente Jahre mit einem Kurssturz auf 1,726 Euro hinter sich gebracht. Der Aktienkurs des französischen Impfstoff-Entwicklers befindet sich seit Ende 2024 aber wieder in einer... ► Artikel lesen | |
| BIOFRONTERA | 2,360 | -3,28 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,600 | +0,87 % | Contrarius Global Equity Fund's Thoughts on CRISPR Therapeutics' (CRSP) Gene Editing Therapy | ||
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,419 | +4,23 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,850 | +0,56 % | Cathie Wood's ARK makes strategic stock moves, buys Intellia and sells Roku | ||
| BIO-GATE | 0,800 | -1,84 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,440 | +3,04 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,459 | -1,83 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,827 | -1,78 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,900 | +5,84 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| ATAI BECKLEY | 3,391 | +0,36 % | AtaiBeckley N.V.: AtaiBeckley Completes Redomiciliation to the United States | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing... ► Artikel lesen | |
| IMMUNITYBIO | 1,764 | +0,97 % | ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe | ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,855 | +1,18 % | Onco-Innovations Limited: Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care | VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") is pleased to announce, further to its... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,340 | -1,35 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen |
IO BIOTECH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,025 (+4,34 %) liegt der Kurs bei 0,606 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IO BIOTECH INC finden Sie auf Wallstreet Online.